Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Camp4 Therapeutics (CAMP) Shares Outstanding (Diluted Average) (2023 - 2025)

Historic Shares Outstanding (Diluted Average) for Camp4 Therapeutics (CAMP) over the last 3 years, with Q3 2025 value amounting to $27.3 million.

  • Camp4 Therapeutics' Shares Outstanding (Diluted Average) rose 479287.96% to $27.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.3 million, marking a year-over-year increase of 479287.96%. This contributed to the annual value of $4.7 million for FY2024, which is 108743.77% up from last year.
  • Camp4 Therapeutics' Shares Outstanding (Diluted Average) amounted to $27.3 million in Q3 2025, which was up 479287.96% from $20.2 million recorded in Q2 2025.
  • In the past 5 years, Camp4 Therapeutics' Shares Outstanding (Diluted Average) registered a high of $27.3 million during Q3 2025, and its lowest value of $394976.0 during Q4 2023.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $8.3 million, with a median of $557437.0 in 2024.
  • As far as peak fluctuations go, Camp4 Therapeutics' Shares Outstanding (Diluted Average) soared by 3921.1% in 2024, and later skyrocketed by 479287.96% in 2025.
  • Over the past 3 years, Camp4 Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $394976.0 in 2023, then skyrocketed by 1087.44% to $4.7 million in 2024, then skyrocketed by 481.54% to $27.3 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $27.3 million for Q3 2025, versus $20.2 million for Q2 2025 and $20.2 million for Q1 2025.